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Abstract: The clinical outcome of cardiovascular diseases as myocardial infarction and stroke are generally caused by 
rupture of an atherosclerotic plaque. However, the actual cause of a plaque to rupture is not yet established. Interestingly, 
pathology studies have shown an increased presence of the mast cell, an important inflammatory effector cell in allergy 
and host defense, in (peri)vascular tissue during plaque progression, which may point towards a causal role for mast cells. 
Very recent data in mouse models show that mast cells and derived mediators indeed can profoundly impact plaque pro-
gression, plaque stability and acute cardiovascular syndromes such as vascular aneurysm or myocardial infarction. In this 
review, we discuss recent evidence on the role of mast cells in the progression of cardiovascular disorders and give insight 
in the therapeutic potential of modulation of mast cell function in these processes to improve the resilience of a plaque to 
rupture.  
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1. INTRODUCTION 
  Already in 1876 during his thesis research Paul Ehrlich 
discovered a new, highly potent inflammatory cell type and 
designated it “mast cell”, after the basophilic storage gran-
ules [1-3]. Mast cells were found to respond to various ex-
ogenous signals from bacteria, viruses and parasites via rec-
ognition receptors, such as Toll-like receptors and immuno-
globulins [4-6]. Mast cells are not only involved in first line 
defence against pathogens but also represent important me-
diators  in  diseases  such  as  allergy  and  asthma,  once  they 
become dysregulated in response to an excess of allergen or 
allergen-specific IgE [5, 6]. Mast cells are laden with gran-
ules containing a wide variety of mediators, such as the pro-
teases chymase, tryptase and the cathepsins, the vasoactive 
histamine, heparin and a plethora of cytokines such as Tu-
mor Necrosis Factor α (TNFα), chemokines (e.g. Interleukin 
8 (IL-8)) and other growth factors (e.g. Vascular Endothelial 
Growth  Factor  (VEGF),  basic  Fibroblast  Growth  Factor 
(bFGF)) [6].  
  Acute  cardiovascular  syndromes,  such  as  myocardial 
infarction and vascular aneurysm formation, are still a major 
cause of death on the Western society. Atherosclerosis, one 
of the main cardiovascular disorders causing the acute car-
diovascular  events,  is  considered  a  chronic  inflammatory 
disease, involving many inflammatory cells such as macro-
phages  and  T-lymphocytes  [7,  8].  At  later  stages,  when 
plaques become clinically manifest, thrombosis, coagulation 
and fibrinolysis will contribute to the escalation of the dis-
ease, which culminates in acute cardiovascular syndromes. 
Mast cells reside in the perivascular tissue of healthy arteries 
and  during  the  progression  of  atherosclerosis,  the  cells  
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accumulate in the adventitia and the shoulder region of the 
atherosclerotic plaque. Also the heart is one of the organs 
rich in mast cells. The whole array of mediators released by 
mast cells after its activation suggests that they could be in-
volved  in  the  development  of  atherosclerosis  and  vascular 
aneurysm  formation,  in  which  immune  cells  were  demon-
strated to play a central role. However, it remains to be elu-
cidated whether mast cells are actively modulating the mor-
phology of the arterial wall,  thereby being instrumental in 
atherosclerotic  plaque  development  and  progression,  aneu-
rysm formation or causing plaque rupture. 
  In this review, we will outline present knowledge on the 
contribution of mast cells to cardiovascular diseases in gen-
eral. Particular emphasis will be on the pathobiologies with 
an  inflammatory  component  such  as  the  development  and 
progression of atherosclerosis, as well as to myocardial in-
farction and vascular aneurysm formation. Furthermore, we 
will discuss in vitro and in vivo models that have recently 
given more insight into the mechanisms by which mast cells 
exert their pathogenic effects. Finally, the therapeutic poten-
tial of modulation of mast cell function will be evaluated. 
2. TECHNIQUES IN MAST CELL RESEARCH 
  Human pathology studies have provided ample evidence 
for the presence of a variety of immune and inflammatory 
cell types in diseased tissue and these studies have been es-
sential in identifying the major cellular players in the pro-
gression of disease. Mast cells can easily be detected in tis-
sue sections through a variety of mast cell staining protocols 
that  are  available  at  present.  Toluidin  Blue  as  well  as  a 
Chloro-Acetate Esterase (CAE) staining both stain the granu-
lae  of  mast  cells  [9],  while  immunohistochemical  analysis 
for  CD117,  tryptase  or  chymase  can  help  to  conclusively 
identify mast  cell presence in  tissues.  Mucosal  mast  cells, 
present in e.g. lung and colon tissue and connective tissue 
type mast cells found in tissues like the perivascular tissue 
can be distinguished by an Alcian Blue/Saphranin O staining 
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  Animal models have greatly facilitated to understand the 
molecular mechanisms involved in cardiovascular diseases, 
be  it  atherosclerosis,  ischemia/reperfusion  injury,  or  aneu-
rysm formation. In atherosclerosis, e.g. high fat diet fed rab-
bits and genetically modified hyperlipidemic mice, such as 
the ApoE
-/- [12, 13], LDLr
-/- [14] or the ApoE3Leiden trans-
genic mice [15] have all been demonstrated to develop athe-
rosclerotic plaques in aortic valve area, the aortic arch and 
carotid arteries and can be used for intervention studies. To 
induce myocardial infarction, coronary artery ligation mod-
els have been developed resulting in ischemia of the heart, 
often followed by reperfusion to study the inflammatory re-
sponse [16, 17]. Likewise, a number of models have been 
described to identify key players in vascular aneurysm for-
mation, which are generally based on elastase perfusion of 
the  aorta  [18],  peri-aortic  chemical  injury  [19],  arterial 
clamping [20] or Angiotensin II infusion in atherosclerotic 
ApoE
-/- mice [21].  
  Mast  cell  deficient  animals  were  reported  already  in 
1978, when Kitamura and colleagues first described W/Wv 
mice that were virtually devoid of tissue and skin mast cells 
[22]. These mice, besides being anemic, sterile and lack of 
hair pigmentation, were demonstrated to only have 1% of the 
normal  number  of  skin  mast  cells  compared  to  wild-type 
mice,  while  in  other  tissues  of  these  mice  mast  cells  are 
completely absent. W/Wv mice were found to carry a muta-
tion in the C-Kit gene which results in an intrinsic defect in 
hematopoietic  stem  cells  and  dysregulated  hematopoiesis. 
Injection  of  these  mice  with  bone  marrow  from  wild-type 
mice resulted  in  a repopulation of mast cells. The anemic 
Sl/Sl
d  mouse  has  a  comparable  phenotype  as  the  W/Wv 
mouse, however in this strain bone marrow transfer does not 
rescue the phenotype, suggesting that in these mice environ-
mental factors needed to induce mast cell differentiation and 
maturation are absent [23, 24]. A mutation of the C-kit gene 
in  the  white  spotting  (Ws)  locus  resulted  in  the  mast  cell 
deficient  Ws/Ws  rat  [25].  More  recently,  a  new  mast  cell 
deficient mouse was described that bears the spontaneously 
arisen W-sash (W
sh) inversion mutation. Unlike the previous 
two strains, mast cell deficiency is not accompanied by ane-
mia and sterility [26]. These Kit(W
-sh/W
-sh) mice can also be 
repopulated with mast cells by injection of either bone mar-
row  cells  or  cultured  bone  marrow  derived  mast  cells 
(BMMCs),  rendering  this  mouse  a  very  interesting  animal 
for studying mast cell biology in vivo.  
  Another  approach  in  mast  cell  research,  albeit  not  fre-
quently pursued in cardiovascular disease models, involves 
systemic or focal mast cell activation in animals. To date, 
most  research  has  been  conducted  in  disease  models  of 
asthma, allergy and arthritis. Mast cells can be activated in 
various ways, of which IgE stimulation and hapten sensitiza-
tion/challenge are widely known [27, 28]. Compound 48/80 
is a well-known mast cell activator used in in vitro as well as 
in vivo studies [29]. In the next sections, human pathology 
studies as well as the use of in vitro and in vivo models in-
vestigating the role of mast cells and mast cell constituents in 
cardiovascular disorders will be described. 
3. MAST CELLS IN ATHEROSCLEROSIS 
  Already in 1953, Constantinides reported that mast cells 
might be involved in the susceptibility to experimental athe-
rosclerosis [30]. In this study, the author suggested that the 
heparin stored in mast cell granules could be atheroprotec-
tive. In a follow up study in 1954, Constantinides and co-
workers stated that myocardial tissue from patients suffering 
from  atherosclerosis  displayed  reduced  numbers  of  mast 
cells per microscopic field compared to younger individuals 
not suffering from atherosclerosis [31]. As already demon-
strated in his first report on experimental atherosclerosis, this 
phenomenon was again attributed to the atheroprotective role 
of mast cell derived heparin [30]. In the following decades, 
the  paradigm  gradually  shifted  towards  a  pro-atherogenic 
role for mast cells, as mast cell numbers in the intima, media 
as well as in the perivascular tissue (the adventitia), were in 
fact found to be increased with the progression of atheroscle-
rosis [32].  
  Mast  cell  constituents  such  as  histamine,  prostaglandin 
D2  and  leukotrienes  play  a  role  in  atherogenesis  and  its 
clinical manifestations by affecting endothelial cell function 
and  vasoreactivity.  This  hypothesis  is  strengthened  by  the 
recent finding that increased mast cell numbers in the adven-
titia  of  coronary  arteries  associate  with  vasospasms  [33]. 
Chymase,  a mast  cell protease,  can contribute to vasocon-
striction by converting Angiotensin I into the vasoactive An-
giotensin  II  (AngII),  independently  of  Angiotensin-I  Con-
verting Enzyme (ACE) [34, 35]. Furthermore, chymase has 
been demonstrated to convert big endothelin-1 (ET-1) to 31-
amino  acid-length  endothelins,  ETs(1-31),  which  also  act 
vasoconstrictive [36, 37].  
  Although mast cells were on one hand demonstrated to 
inhibit macrophage induced oxidation of Low Density Lipo-
protein (LDL) [38, 39], mast cells have on the other hand 
been suggested to contribute to atherogenesis through secre-
tion  of  heparin  proteoglycans  (HPG)  containing  granules, 
which in turn bind LDL. HPG bound LDL can subsequently 
be  captured  in  the  intima  by  phagocytosing  macrophages, 
leading to enhanced lipid accumulation and lesion progres-
sion [40, 41]. Additionally, mast cell chymase is able to de-
grade apoE and apoAII, leading to a reduction of cholesterol 
efflux  from  macrophages  to  these  apolipoproteins,  which 
enhances  foam  cell  formation  [42].  Furthermore,  oxidized 
LDL (OxLDL), modified in the intima, can induce mast cell 
degranulation,  resulting  in  atherosclerotic  lesion  expansion 
through  a  self-amplifying  cascade  and  moreover  through 
increased leukocyte influx [43, 44]. Secretion of chemokines 
Monocyte Chemotactic Protein-1 (MCP-1) and IL-8 by mast 
cells will also increase leukocyte influx into the plaque [45]. 
Mast cell progenitors could be recruited to the plaque as well 
during  plaque  progression  together  with  other  pro-inflam-
matory cells such as monocytes and lymphocytes. Haley et 
al.  described  the  presence  of  CCR3  positive  mast  cells  in 
plaques of atherosclerotic arteries, while the primary ligand 
of CCR3, eotaxin, was demonstrated to be highly expressed 
by activated vascular smooth muscle cells [46], suggesting 
that the chemokine receptor CCR3 is involved in this proc-
ess.  
  Foci of mast cell accumulation were detected in the in-
tima  at  later  stages  of  plaque  formation,  mainly  near  the 
shoulder  region  and  in  areas  of  early  calcification  of  the 
plaque  [47-50].  As  described  above,  these  mast  cells  may 
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eotaxin and adhere to the plaque surface or to extracellular 
matrix  components  such  as  fibronectin,  vitronectin  or 
laminin via integrins and adhesion molecules like intercellu-
lar adhesion molecule (ICAM)-1 [51]. In addition, mast cells 
may also be (co-)activated upon binding to extracellular ma-
trix molecules, thereby releasing a variety of cytokines into 
its environment [52, 53]. 
  Intimal  mast  cells  have  been  demonstrated  to  contain 
tryptase, and approximately 40% of the cells contained chy-
mase as well [50]. Both mast cell proteases were able to ac-
tivate matrix metalloproteinases (MMPs) leading to degrada-
tion of collagen and elastin [54-56], consequently resulting 
in further destabilization of the plaque. As Kovanen and col-
leagues demonstrated, increased numbers of activated mast 
cells have been identified in particular in the adventitia of 
vulnerable and ruptured lesions in patients with myocardial 
infarction
 and more importantly, their number was found to 
correlate with  the  incidence of plaque rupture  and erosion 
[57-59]. Both may lead to thrombus formation and eventu-
ally to acute coronary syndromes such as myocardial infarc-
tion. Mast cell activation has recently been demonstrated to 
have a potential role in the process of endothelial desquama-
tion  by  demonstrating  that  the  number  of  subendothelial 
mast  cells  correlated  with  the  number  of  parietal  mi-
crothrombi, which may have formed at sites of partial plaque 
erosion [60, 61]. 
  It is not completely clear whether or not adventitial mast 
cells  are  capable  of  modulating  intimal  processes  and  in-
strumental in plaque rupture, although most evidence points 
in that direction. Pathology studies so far suggest that adven-
titial  mast  cells indeed contribute to plaque destabilization 
and plaque rupture, as mentioned above by release of mast 
cell proteases chymase and tryptase that can directly degrade 
matrix molecules themselves but also by activation of MMPs 
and by conversion of AngI into the proinflammatory, vasoac-
tive AngII [62]. Secondly, mast cells were reported to induce 
apoptosis of cardiomyocytes [63], vascular smooth muscle 
cells [64-66] and endothelial cells [67, 68] in vitro, which 
could translate in reduced plaque stability
 [69, 70].  
  A  third  mechanism  through  which  mast  cells  can  con-
tribute  to  plaque  progression  and  destabilization  is  by  en-
hancing neovascularization of the plaque. Indeed, in neovas-
cularized  areas  of  human  coronary  atheromas  mast  cells 
were demonstrated to colocalize with intraplaque microves-
sels
 [71]. In vitro studies showed endothelial proliferation in 
response to mitogenic factors. Conceivably, VEGF secreted 
by mast cells
 [72] could result in enhanced outgrowth of mi-
crovessels.  Mast  cells  containing  basic  Fibroblast  Growth 
Factor (bFGF), a potent angiogenic factor, were located near 
microvessels in the intima and adventitia of human coronary 
artery lesions [73], suggestive of a role of these mast cells in 
neo-angiogenesis. Furthermore, mast cells may, by releasing 
the  vasoactive  agent  histamine,  contribute  to  microvessel 
leakage and intraplaque hemorrhage [71].  
  Only recently, experimental proof was provided in sup-
port of a role of mast cells in atherosclerotic plaque devel-
opment and progression. Sun et al. used the mast cell defi-
cient Kit(W
-sh/W
-sh) mice, which had been backcrossed with 
the atherosclerotic LDLr
-/- mouse [74]. Atherogenesis in the 
mast cell deficient LDLr
-/- mice was hampered compared to 
control  LDLr
-/- mice. Importantly,  lipid deposition, macro-
phage  content  and  plaque  apoptosis  were  reduced,  while 
collagen  content  and  fibrous  cap  development  were  in-
creased in these mice, reflective of a more stable phenotype 
of mast cell deficient plaques. Repopulation of these mice 
with wild-type BMMCs completely reversed the beneficial 
effect of mast  cell  absence. Adoptive transfer of IL-6
-/- or 
IFNγ
-/- BMMCs did however not affect lesion progression, 
implying that mast cell-derived IL-6 and IFNγ are the prime 
factors in mast cell dependent plaque initiation. This elegant 
study  conclusively  demonstrates  the  contribution  of  mast 
cells to the progression of atherosclerosis, however left un-
answered  whether  mast  cells  modulate  the  atherogenic  re-
sponse focally or alter the immune status of the mice, in par-
ticular  as  intimal  mast  cells  are  rather  scarce  in  mouse 
plaques.  
  In  a  parallel  study  by  us,  we  have  pursued  a  different 
strategy to address the direct role of vascular mast cells. We 
have applied slightly constrictive perivascular silastic collars 
at  the  carotid  arteries  of  apoE
-/-  mice  to  stimulate  flow-
induced atherosclerotic plaque formation [75]. After the de-
velopment  of  advanced  atherosclerotic  plaques,  we  sensi-
tized the mice and subsequently activated perivascular mast 
cells focally at the lesion site by adventitial application of a 
pluronic gel containing a hapten to induce mast cell activa-
tion. Focal mast cell activation in the perivascular tissue of 
advanced plaques sharply increased the  incidence of intra-
plaque  hemorrhage  and  macrophage  apoptosis,  the  latter 
being both mast cell protease and histamine dependent [76]. 
Surprisingly,  microvascular  leakage  was  highly  enhanced 
after mast cell activation, which might be responsible for the 
increased intraplaque bleeding. Furthermore, mast cell acti-
vation  resulted  in  enhanced  leukocyte  recruitment  to  the 
plaque, which was CXCR2 and VLA-4-mediated. Most im-
portantly,  treatment  with  the  mast  cell  stabilizer  cromolyn 
prevented all of the undesirable phenomena elicited by mast 
cell activation, rendering mast cell stabilization a new thera-
peutic  approach  in  the  prevention  of  acute  coronary  syn-
dromes.  
  Mast cell function in cardiovascular disease was recently 
shown  to  be  in  part  dependent  on  galectin-3,  which  is  a 
member  of  N-acetyllactosamine-binding
  lectin  family  ex-
pressed  amongst  others  by  mast  cells  [77].  Galectin-3
-/-
/apoE
-/- showed  an impaired atherogenic response as  com-
pared to  apoE
-/- mice, while plaques of galectin-3
-/-/apoE
-/- 
mice had a lower number of perivascular inflammatory infil-
trates and mast cells than those of apoE
-/- mice [78]. 
  The  triggers  that  activate  mast  cells  during  lesion  pro-
gression and plaque rupture are still subject to investigation. 
As described above, mast cells can be activated by modified 
LDL particles which concurs with the notion that bioactive 
phospholipid components might activate mast cells [43, 44], 
while mast cells have also been described to colocalize with 
nerve  endings  [58,  59,  79].  Interestingly,  mast  cells  have 
previously been demonstrated to be activated by various neu-
ropeptides [80, 81] and stress was seen to  induce massive 
histamine release by mast cells [82]. The presence of neu-
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and the plaque renders neuron-mediated mast cell activation 
a plausible mechanism in cardiovascular diseases. 
4. MAST CELLS IN AORTIC VALVE STENOSIS 
  Aortic  valve  stenosis  (AS)  shares  many  features  with 
atherosclerosis,  including  infiltration  of  inflammatory  cells 
such  as  macrophages  and  T-lymphocytes,  accumulation  of 
oxidized  lipids  and  extensive  tissue  remodeling  [83,  84]. 
Analogous  to  atherosclerosis,  also  in  the  diseased  aortic 
valve area  mast  cells were demonstrated  to be abundantly 
present, as visualized by CD117 immunoreactivity and tolu-
idin blue  staining [85]. The molecular  mechanisms of this 
pathological  process  still  remains  to  be  elucidated.  A  few 
years ago, AngII was suggested to contribute to the patho-
genesis of aortic valve stenosis [86]. In this study, Angio-
tensin  I  Converting  Enzyme  (ACE)  mRNA  was  demon-
strated to be upregulated in the stenotic aortic valve and to 
co-localize with macrophages. Interestingly, also mRNA of 
chymase, which, as mentioned above, is an AngII producing 
enzyme as well, was significantly upregulated in these steno-
tic valve areas, while also the number of mast cells as well as 
the degree of degranulation was highly increased. Further-
more, cathepsin G co-localized with mast cells in these dis-
eased  regions  [87].  Hence,  current  evidence  suggests  that 
mast cells are implicated in valve remodeling and AS pro-
gression as well, although more research is necessary to de-
lineate  the  exact  contribution  of  mast  cells  to  this  disease 
process.  
5. MAST CELLS AND MYOCARDIAL INFARCTION 
  Myocardial infarction occurs mainly following rupture of 
an atherosclerotic plaque, leading to thrombus formation and 
vessel occlusion. The heart is a mast cell-rich organ and se-
rum IgE levels were found to be significantly higher in the 
patients  with  unstable  angina  and  acute  myocardial  com-
pared to stable angina pectoris and controls, indicating that 
IgE might play a role in the pathogenesis of unstable angina 
pectoris and acute myocardial infarction [88]. Whole blood 
histamine  levels  from  patients  with  stable  coronary  artery 
disease were elevated compared to control patients and was 
shown to be correlated to isoprostane levels as measure for 
oxidative stress [89], suggesting that histamine might be a 
risk  factor  in  coronary  events.  Serum  tryptase  levels  after 
myocardial infarction may also be altered, albeit that data are 
still subject to some controversy. Van Haelst et al. did not 
detect  any  differences  in  tryptase  levels  between  patients 
with acute myocardial infarction, with unstable angina pecto-
ris or controls that did not suffer from ischemic cardiovascu-
lar diseases [90]. These data have later been confirmed by 
Kervinen  et al. [91]. On  the other hand, Filipiak and  col-
leagues found elevated serum tryptase levels in patients suf-
fering from myocardial  infarction with  an ST-segment de-
pression [92]. In fact tryptase levels were even reported to be 
an independent predictor for future coronary artery disease 
along with age [93].  
  In a guinea pig model of ischemia/reperfusion, histamine 
was  demonstrated  to  be  released  after  an  ischemic  period 
[94]. Mast cell distribution in the heart was investigated after 
induction of acute myocardial infarction in rats, showing a 
clear-cut accumulation of mast cells in the infarcted region 
of the heart [95]. Also in dogs, the number of mast cells was 
highly increased after induction of ischemia/reperfusion in-
jury while macrophages in the infarcted myocardium were 
demonstrated to  express  Stem  Cell Factor (SCF),  a potent 
attractant for mast cells. This led the authors to suggest that 
mast cells are recruited by macrophage derived SCF [96]. 
Mast cell chymase was shown to be upregulated in the in-
farcted left ventricle in a hamster model of MI, while also 
the number of chymase-positive mast cells in that area was 
significantly higher than in the sham operated group. Chy-
mase release could in turn result in enhanced AngII levels 
and indeed, treatment with an AngII type 1 receptor antago-
nist was seen to decrease mortality rates, while an ACE in-
hibitor was ineffective [97]. Apparently, AngII produced by 
mast  cell  derived  chymase  is  involved  in  the  pathophysi-
ologic state of the heart after MI. In support of this hypothe-
sis, treatment of hamsters with specific chymase inhibitors 
(BCEAB,  TEI-E548  and NK3201) improved cardiac func-
tion and mortality rate after the induction of MI [98-100]. 
Furthermore, chymase can also induce cardiomyocyte apop-
tosis  in  vitro  [63]  and  in  swines  that  underwent  coronary 
microembolization,  mast  cell  activation  status  in  the 
ischemic  area  correlated  with  the  percentage  of  apoptotic 
cardiomyocytes [101]. Treatment of these animals with the 
mast cell stabilizer tranilast resulted in a reduction of mast 
cell activation and cardiomyocyte apoptosis, suggesting that 
mast cells contribute to cardiomyocyte apoptosis. 
  In general, mast cells have been demonstrated to accumu-
late in the heart after MI, while the exact role of mast cells 
after  the  MI  however  has  not  completely  been  elucidated. 
Mast cells might on one hand enhance the injury by the re-
lease  of  matrix-degrading  enzymes  such  as  chymase  and 
tryptase and of pro-inflammatory cytokines and chemokines 
resulting in accumulation of inflammatory leukocytes in the 
infarcted area. Also, mast cell activation may aggravate the 
injury by the induction of cardiomyocyte apoptosis. As a rich 
source of VEGF and bFGF however, mast cells may on the 
other  hand  contribute  to  the  wound  healing  response  and 
collateral  formation  after  ischemia.  Further  research  will 
contribute  to  our  understanding  of  the  actual  role  of  mast 
cells in MI. 
6. MAST CELLS IN AORTIC ANEURYSMS  
  Aortic aneurysm development is a chronic degenerative 
condition, which is characterized by weakening and dilation 
of the aortic wall that results in a life-threatening risk of rup-
ture and is associated with the development of atherosclero-
sis [102]. The first study to report a causal relation between 
mast  cell  density  in  the  aortic  wall  and  aneurysm  rupture 
dates already from 1981
 [103], when Faleiro et al. showed a 
more pronounced presence of  mast  cells  in arteries of  the 
circle of Willis of patients that died of subarachnoid hemor-
rhage (SAH) after aneurysm rupture, although the number of 
patients included in this study was very limited. Besides a 
single case study of a patient  that died of coronary artery 
dissection in which the perivascular tissue was demonstrated 
to contain a large eosinophil and mast cell infiltrate [104], 
hardly any studies reported on the contribution of mast cells 
to aneurysm development up to 1999. In that year, Ihara et 
al. [62] conclusively demonstrated that in aneurysmal tissue 
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tase positive mast cells was significantly higher compared to 
non-aneurysmal  atherosclerotic  tissue.  Mast  cell  derived 
chymase, as mentioned before one of the mast cell proteases, 
can  convert  AngI  into  AngII  independent  of  the  classic 
renin-angiotensin  system  (RAS).  Ang  II  in  turn  is  a  very 
important factor in the development of aneurysms  and in-
deed, chymase and AngII converting enzyme (ACE) activity 
were  both  upregulated  in  aneurysmal  aortas  compared  to 
control tissue [105, 106]. These findings were in part con-
firmed by Ejiri et al. [107] who demonstrated that in sections 
of  thoracic  aortic  aneurysm  (TAA)  samples,  chymase-
positive  mast  cells  accumulated  in  the  pro-inflammatory 
regions of TAA tissue, suggestive of  a causal relationship 
between the number of  activated mast  cells and  aneurysm 
rupture. Furthermore, protein extracts prepared from aneu-
rysm tissue were demonstrated to activate pro-matrix metal-
loproteinase-9  (MMP-9)  into  its  active  form  [108],  which 
was demonstrated to be inhibited by the chymase inhibitor 
NK3201,  thereby  defining  yet  another  pathway  by  which 
chymase can contribute to aneurysm development. Tsuruda 
et al. [109] found an increased number of mast cells in ab-
dominal aortic aneurysm (AAA) tissue as compared to athe-
rosclerotic  aortas  without  any  aneurysmal  change.  These 
authors  also  showed  high  immunoreactivity  of  these  mast 
cells  for  adrenomedullin  (AM),  which  exerts  antifibrotic 
actions in cardiovascular remodeling, thus resulting in a re-
duced stability of the vessel wall. In conclusion, although the 
number of human pathology studies on mast cells in aneu-
rysm is limited and the sample sizes of most studies small, 
all  evidence  directs  towards  a  causal  relationship  between 
mast cell numbers and the incidence of aneurysm formation.  
  In vivo studies on the role of mast cell biology in aneu-
rysm formation have been focussed on the mast cell protease 
chymase as an AngII producing enzyme. Chymase was in-
deed demonstrated to be involved in aneurysm development 
in an animal model where AAA was induced by application  
 
of elastase onto the abdominal aorta of hamsters that were 
treated with the specific chymase inhibitor NK3201 [110]. 
The aortic diameter in the NK3201-treated group was sig-
nificantly reduced compared to the control group, indicating 
that  the  chymase  inhibitor  prevented  the  development  of 
AAA in this animal model. Similarly, NK3201 treatment of 
dogs in which AAA was induced by injecting elastase into 
the abdominal aorta, resulted in a reduced ratio of medial and 
total  vessel  area  compared  to  controls  [111].  Collectively 
these studies show that chymase inhibition may be a useful 
therapy for prevention of abdominal aortic aneurysms. 
  Recently, Sun et al. studied the role of mast cells itself 
rather  than  a  specific  mast  cell  constituent  in  an  animal 
model of  abdominal  aortic  aneurysm (AAA) formation, in 
which AAA was induced by elastase perfusion in mast cell 
deficient  Kit(W
-sh/W
-sh)  mice  and  syngenic  control  mice 
[112].  In  this  study,  the  mast  cell-deficient  mice  failed  to 
develop AAA because of reduced aortic expansion and in-
ternal  elastic  lamina  degradation,  while  conversely  com-
pound 48/80 induced mast cell activation in wild-type mice 
resulted even in enhanced AAA growth. Mast cell stabiliza-
tion  with  cromolyn  diminished  AAA  formation  in  wild- 
type mice and the authors demonstrated that mast cells par-
ticipate  in  AAA  formation  by  influencing  angiogenesis, 
vSMC apoptosis, and matrix-degrading protease expression. 
Reconstitution of the Kit(W
-sh/W
-sh) mice with BMMCs from 
wild-type or TNFα
-/- mice caused susceptibility to AAA for-
mation to be recovered while IL-6
-/- or IFNγ
-/- BMMCs were 
ineffective.  
  Similarly, AAA were induced in mast cell-deficient mu-
tant Ws/Ws rats by peri-aortic CaCl2 application, which re-
sulted in a decreased diameter of abdominal aorta compared 
to the aortic diameter of wild-type rats [113]. In the wild-
type rats, AAA formation was accompanied by accumulation 
of mast cells,
 T-lymphocytes, IFNγ positive cells and by ac- 
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tivated MMP-2 and -9, which was inhibited in the mast cell 
deficient  rats  and  interestingly,  these  phenomena  could  be 
inhibited by treatment with the mast cell stabilizer tranilast.  
  In conclusion, these studies demonstrate that mast cells 
may not only participate in AAA pathogenesis by inducing 
aortic SMC apoptosis and by releasing proteases  like chy-
mase and tryptase, but also have a role in the inflammatory 
response in aneurysm development. 
7. CONCLUSIONS AND THERAPEUTIC POTENTIAL 
  Culminating evidence from pathology and experimental 
studies points to a key role for mast cells not only in a range 
of immune diseases but also in various cardiovascular disor-
ders. Perivascular as well as intimal mast cells were seen to 
contribute substantially to the pathogenesis of atherosclerosis 
and  plaque  destabilization  (Fig.  (1)).  Mast  cells  promote 
lipid  accumulation,  matrix  degradation,  apoptosis,  increase 
leukocyte influx into the plaque and enhance microvascular 
leakage,  all  resulting  in  a  sharply  increased  risk  of  intra-
plaque hemorrhage, plaque destabilization and rupture. Sec-
ond, mast cells contribute importantly to aneurysm formation 
by  the  release  of  chymase,  while  also  mast  cell  IL-6  and 
IFNγ were seen to be involved. A role of mast cells in the 
response  after  acute  myocardial  infarction  seems  plausible 
but still awaits experimental support. Intervention studies in 
cardiovascular disease models so far (Table 1) have revealed 
a number of promising leads that target pathogenic mast cells 
per se (mast cell stabilizers) or mast cell constituents such as 
chymase, tryptase, histamine, IFNγ and IL6, which may have 
high therapeutic potential in the prevention of plaque rup-
ture, aneurysm formation and possibly other cardiovascular 
disorders.  
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